Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 76Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Burkitt Lymphoma 16Recurrence 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms, Plasma Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Leukemia 4Neoplasm Metastasis 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Hairy Cell 2Hodgkin Disease 2Fatigue 2Brain Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2

Interventions

Dexamethasone 17Lenalidomide 15Bortezomib 12Cyclophosphamide 7fludarabine 6carfilzomib 6Melphalan 6daratumumab 5Calcium Dobesilate 5pomalidomide 3gamma-Globulins 3fludarabine phosphate 3belantamab mafodotin 3Whole-Body Irradiation 3Trimethoprim, Sulfamethoxazole Drug Combination 3Tacrolimus 3Mycophenolic Acid 3isatuximab 2elotuzumab 2Sirolimus 2Prednisone 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Ciprofloxacin 2Amoxicillin-Potassium Clavulanate Combination 2venetoclax 1thymoglobulin 1siltuximab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Calcium Dobesilate × 1 year × Clear all
NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
33 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

Dana-Farber Cancer Institute

Phase 3 Active not recruiting
729 enrolled 29 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Alliance Foundation Trials, LLC.

Phase 1 Completed
14 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
49 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡